The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Diagnosed with stage 4 lung cancer in 2020, Sanjay Dutt turned to chemotherapy, exercise, and family support in his fight ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Amplia Therapeutics and Immutep have released clinical trial results that promise more effective treatments for pancreatic and lung cancers ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Helene Duhamel was recently diagnosed with non-small cell squamous cell lung cancer. Duhamel shares her thoughts on her ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, together with its esteemed partners Heidelberg University Hospital, European Institute of ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, ...